Gene transfer into the liver of nonhuman primates with E1-deleted recombinant adenoviral vectors: Safety of readministration

Human Gene Therapy

Volumn 10, Issue 15, 1999, Pages 2515-2526

  Nunes, Frederick A ^a   Furth, Emma E ^a   Wilson, James M ^a   Raper, Steven E ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b 607 Biomed Research Building II/III ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VECTOR;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; GENE DELETION; GENE EXPRESSION REGULATION; GENE TRANSFER; HISTOCHEMISTRY; IMMUNE RESPONSE; LIVER BIOPSY; LIVER PARENCHYMA; MARKER GENE; NONHUMAN; RHESUS MONKEY; VIRUS RECOMBINANT;

ADENOVIRIDAE; ADENOVIRUS E1 PROTEINS; ANIMALS; FEMALE; GENE DELETION; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HELA CELLS; HUMANS; LIVER; MACACA MULATTA; MALE; MICROSCOPY, ELECTRON; NEUTRALIZATION TESTS; RECOMBINATION, GENETIC;

ADENOVIRIDAE; ANIMALIA; DNA VIRUSES; MACACA MULATTA; PRIMATES;

EID: 0033543994     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430349950016852     Document Type: Article

References (22)

1. DAI, Y., SCHWARZ, E.M., GU, D., ZHANG, W.W., SARVETNICK, N., and VERMA, I.M. (1995). Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: Tolerization of factor IX and vector antigens allows for long-term expression. Proc. Natl. Acad. Sci. U.S.A. 92(5), 1401-1405.
2. ENGELHARDT, J.F., LITZKY, L., and WILSON, J.M. (1994a). Prolonged transgene expression in cotton rat lung with recombinant adenoviruses defective in E2a. Hum. Gene Ther. 5(10), 1217-1229.
3. ENGELHARDT, J.F., YE, X., DORANZ, B., and WILSON, J.M. (1994b). Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc. Natl. Acad. Sci. U.S.A. 91 (13), 6196-6200.
4. GAO, G.P., YANG, Y., and WILSON, J.M. (1996). Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J. Virol. 70(12), 8934-8943.
5. JAFFE, H., DANEL, G., LONGENECKER, G., METZGER, M., SETOGUCHI, Y., ROSENFELD, M., GANT, T., THORGEIRSSON, S., STRATFORD-PERRICAUDET, L., PERRICAUDET, M., PAVIRANI, A., LECOCQ, J., and CRYSTAL, R. (1992). Adenovirus-mediated in vivo gene transfer and expression in normal rat liver. Nature Genet. 1, 372-378.
6. JOOSS, K., ERTL, H.C., and WILSON, J.M. (1998). Cytotoxic T-lymphocyte target proteins and their major histocompatibility complex class I restriction in response to adenovirus vectors delivered to mouse liver. J. Virol. 72(4), 2945-2954.
7. KAY, M.A., HOLTERMAN, A., MEUSE, L., GOWN, A., OCHS, H.D., LINSLEY, P.S., and WILSON, C.B. (1995). Long-term hepatic adenovirus-mediated gene expression in mice following CTLA-4Ig administration. Nature Genet. 11, 191-197.
8. KNODELL, R., ISHAK, K., BLACK, W., CHEN, T., CRAIG, R., KAPLOWITZ, N., KIERNAN, T., and WOLLMAN, J. (1981). Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1, 431-435.
9. KOZARSKY, K.F., and WILSON, J.M. (1993). Gene therapy: Adenovirus vectors. Curr. Opin. Genet. Dev. 3(3), 499-503.
10. MORSY, M., GU, M., MOTZEL, S., et al. (1998). An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc. Natl. Acad. Sci. U.S.A. 95, 7866-7871.
11. RAPER, S.E., HASKAL, Z.J., YE, X., PUGH, C., FURTH, E.E., GAO, G.P., and WILSON. J.M. (1998a). Selective gene transfer into the liver of non-human primates with E1-deleted, E2A-defective, or E1-E4 deleted recombinant adenoviruses. Hum. Gene Ther. 9(5), 671-679.
12. RAPER, S.E., WILSON, J.M., YUDKOFF, M., ROBINSON, M.B., YE, X., and BATSHAW, M.L. (1998b). Developing adenoviral-mediated in vivo gene therapy for ornithine transcarbamylase deficiency. J. Inner. Metab. Dis. 21(Suppl. 1), 119-137.
13. SULLIVAN, D.E., DASH, S., DU, H., HIRAMATSU, N., AYDIN, F., KOLLS, J., BLANCHARD, J., BASKIN, G., and GERBER, M.A. (1997). Liver-directed gene transfer in non-human primates. Hum. Gene Ther. 8, 1195-1206.
14. YANG, Y., RAPER, S.E., COHN, J.A., ENGELHARDT, J.F., and WILSON, J.M. (1993). An approach for treating the hepatobiliary disease of cystic fibrosis by somatic gene transfer. Proc. Natl. Acad. Sci. U.S.A. 90(10), 4601-4605.
15. YANG, Y., ERTL, H.C., and WILSON, J.M. (1994a). MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity 1(5), 433-442.
16. YANG, Y., NUNES, F.A., BERENCSI, K., FURTH, E.E., GONCZOL, E., and WILSON, J.M. (1994b). Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci. U.S.A. 91(10), 4407-4411.
17. YANG, Y., NUNES, F.A., BERENCSI, K., GONCZOL, E., ENGELHARDT, J.F., and WILSON, J.M. (1994c). Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nature Genet. 7(3), 362-369.
18. YANG, Y., TRINCHIERI, G., and WILSON, J.M. (1995a). "Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nature Med. 1(9), 890-893.
19. YANG, Y., XIANG, Z., ERTL, H.C., and WILSON, J.M. (1995b). Upregulation of class I major histocompatibility complex antigens by interferon gamma is necessary for T-cell-mediated elimination of recombinant adenovirus-infected hepatocytes in vivo. Proc. Natl. Acad. Sci. U.S.A. 92(16), 7257-7261.
20. YANG, Y., SU, Q., and WILSON, J.M. (1996). Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs. J. Virol. 70(10), 7209-7212.
21. YE, X., ROBINSON, M.B., BATSHAW, M.L., FURTH, E.E., SMITH, I., and WILSON, J.M. (1996). Prolonged metabolic correction in adult ornithine transcarbamylase-deficient mice with adenoviral vectors. J. Biol. Chem. 271(7), 3639-3646.
22. YE, X., GAO, G.-P., PABIN, C., RAPER, S., and WILSON, J. (1998). Evaluating the potential of germline transmission after intravenous administration of recombinant adenovirus in the C3H mouse. Hum. Gene Ther. 9(14), 2135-2142.